Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus docetaxel as cross-line second-line therapy in metastatic NSCLC
ChiCTR2500106236Phase 4Not yet recruiting
- Sponsor
- The First People's Hospital of Jingzhou
- Start
- Jul 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab and docetaxel in non-small cell lung cancer (NSCLC), sponsored by The First People's Hospital of Jingzhou. Primary endpoint: 6-month progression-free survival rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
tislelizumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500106236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106236.